NCT02149303 - Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa | Biotech Hunter

Enrollment

191

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions

Atrial FibrillationHemorrhage

Interventions

DRUG

Dabigatran 75 mg

PO BID

DRUG

Dabigatran 150 mg

PO BID

Trial Locations (5)

1160.200.02 Boehringer Ingelheim Investigational Site, Boston

1160.200.06 Boehringer Ingelheim Investigational Site, Boston

1160.200.01 Boehringer Ingelheim Investigational Site, Brooklyn

1160.200.05 Boehringer Ingelheim Investigational Site, Stony Brook

1160.200.03 Boehringer Ingelheim Investigational Site, Austin